Physician profile
Lester Robertson
NPI 1902810500
$18,038.31
in general payments reported to CMS, 2019-2025
70 companies · $2,484 in 2025
The $2,484 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,444 · 2020: $1,241 · 2021: $1,814 · 2022: $2,727 · 2023: $2,774 · 2024: $2,555 · 2025: $2,484.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,806 · Education: $6.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,805.70 |
| Education | $6.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,839.44 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,263.87 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $985.47 | 2019-2023 | Kyprolis, Blincyto, Lumakras |
| Pfizer INC. | $916.50 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $776.67 | 2019-2025 | Lynparza, Calquence, Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $685.48 | 2019-2025 | Opdivo, Opdualag, Krazati |
| Regeneron Healthcare Solutions, INC. | $670.05 | 2020-2025 | Libtayo, Lynozyfic |
| Genentech USA, INC. | $669.67 | 2019-2025 | Tecentriq, Avastin, Rozlytrek |
| Janssen Biotech, INC. | $584.23 | 2019-2025 | Rybrevant, Darzalex, Tecvayli |
| Daiichi Sankyo INC. | $534.15 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Gilead Sciences, INC. | $433.36 | 2021-2025 | Trodelvy |
| Celgene Corporation | $424.39 | 2019-2025 | Pomalyst, Opdivo, Reblozyl |
| Genzyme Corporation | $412.95 | 2019-2025 | |
| Lilly USA, LLC | $345.77 | 2019-2023 | Verzenio, Jaypirca, Retevmo |
| Seagen INC. | $345.05 | 2019-2023 | Tukysa, Adcetris, Padcev |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $338.61 | 2019-2025 | Padcev, Xtandi |
| Abbvie INC. | $327.43 | 2019-2025 | Venclexta |
| Eisai INC. | $299.32 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $272.33 | 2019-2025 | Ninlaro, Iclusig, Fruzaqla |
| Bayer Healthcare Pharmaceuticals INC. | $241.61 | 2019-2025 | |
| Glaxosmithkline, LLC. | $223.43 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Ipsen Biopharmaceuticals, INC | $218.65 | 2019-2024 | Onivyde, Somatuline Depot |
| Array Biopharma INC | $215.97 | 2021-2025 | Braftovi, Lorbrena, Mektovi |
| Acrotech Biopharma INC. | $210.22 | 2021-2025 | Beleodaq |
| Beigene USA, INC. | $182.04 | 2022-2025 | Brukinsa |
| Kite Pharma, INC. | $162.65 | 2021-2025 | Yescarta |
| Incyte Corporation | $150.27 | 2019-2025 | Jakafi |
| Puma Biotechnology, INC. | $142.98 | 2019-2025 | |
| Exelixis INC. | $129.58 | 2021-2024 | Cabometyx |
| Stemline Therapeutics INC. | $127.27 | 2023-2025 | Orserdu |
| Emd Serono, INC. | $125.39 | 2019-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $108.17 | 2019-2023 | Imbruvica |
| Taiho Oncology, INC. | $105.11 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $104.12 | 2019-2023 | Gilotrif |
| Alexion Pharmaceuticals, INC. | $95.53 | 2019-2024 | Ultomiris |
| Jazz Pharmaceuticals INC. | $84.49 | 2019-2023 | Zepzelca |
| Rigel Pharmaceuticals, INC. | $78.85 | 2021-2025 | Rezlidhia, Tavalisse, Gavreto |
| Tersera Therapeutics LLC | $75.23 | 2019-2021 | |
| Beone Medicines USA, INC. | $71.87 | 2025 | Brukinsa |
| Tesaro, INC. | $70.57 | 2019 | |
| Deciphera Pharmaceuticals INC. | $68.63 | 2024-2025 | Qinlock, Tgct, Romvimza |
| Myovant Sciences INC. | $67.62 | 2021 | |
| Kyowa Kirin, INC. | $66.39 | 2019 | |
| Sumitomo Pharma America, INC. | $60.56 | 2023-2025 | Orgovyx |
| Sobi, INC | $56.98 | 2022-2025 | |
| Geron Corporation | $51.56 | 2025 | Rytelo |
| Adc Therapeutics America, INC. | $44.68 | 2025 | |
| Morphosys, US INC. | $42.75 | 2021-2023 | Monjuvi |
| Karyopharm Therapeutics INC. | $41.30 | 2023 | Xpovio |
| G1 Therapeutics, INC. | $37.49 | 2023 | Cosela |
| Mylan Institutional INC. | $32.52 | 2022 | |
| Sun Pharmaceutical Industries INC. | $31.78 | 2021-2022 | |
| Clovis Oncology, INC. | $31.37 | 2019-2022 | |
| Dova Pharmaceuticals | $30.80 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $29.55 | 2020-2021 | |
| Amag Pharmaceuticals, INC. | $29.14 | 2019 | |
| Global Blood Therapeutics, INC. | $26.85 | 2020-2021 | |
| Csl Behring | $24.69 | 2022 | |
| Pharmacosmos Therapeutics INC. | $24.65 | 2022 | |
| Heron Therapeutics, INC. | $24.29 | 2019 | |
| Eusa Pharma (US) LLC | $22.11 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.94 | 2019 | |
| Octapharma USA, INC. | $18.60 | 2023 | Octagam Immune Globulin (Human) |
| Ge Healthcare | $17.62 | 2022 | |
| Cti Biopharma Corp. | $16.20 | 2023 | Vonjo |
| Aveo Pharmaceuticals, INC. | $16.17 | 2022 | |
| Servier Pharmaceuticals LLC | $15.88 | 2024 | |
| Recordati_rare_diseases_inc. | $14.67 | 2025 | Sylvant |
| Shire North American Group INC | $14.48 | 2019 | |
| Secura Bio, INC. | $10.30 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lester Robertson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.